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1 Abstract	
Searching for novel carbapenemases in zoo animals 
Degree project, Programme in Medicine 
Martin Thorslund 
2018, Institute of Biomedicine, Gothenburg, Sweden 1.1 Introduction	
Carbapenems, a class of “last resort” antibiotics, are threatened by resistant pathogens 
producing carbapenemases. There is increasing evidence that the environmental/commensal  
bacteria act as a source of antibiotic resistance genes that can be picked up by pathogens. 
Sampling animal microbiota could increase the probability of finding genes that have the 
potential to migrate the pathogens. 1.2 Aim	
To screen for novel carbapenemases in the stool of animals never purposely exposed to 
carbapenems.  1.3 Methods	and	results	
By inoculating fecal samples from 43 zoo animals in meropenem-supplemented broths, 31 
meropenem-resistant strains were isolated; the majority could be identified as opportunistic 
bacteria by MALDI-TOF. Seventeen isolates were positive in Carba NP and imipenem-EDTA 
synergy tests, indicating carriage of genes encoding carbapenemases of the metallo-β-
lactamase (MBL) class. Total DNA was isolated from meropenem-supplemented broths with 
visible growth and sequenced. Through newly developed hidden Markov models, 19 novel 
MBLs were found, 13 novel B1 and 6 novel B3 genes, by screening the sequenced DNA. 
  
 
2 
PCR could link 6 novel B1 and 3 novel B3 MBLs to specific isolates. Samples was also 
pooled into five groups according to their animal origin, 11 novel B1s and 4 novel B3s could 
be linked to one or more of these animal groups. 1.4 Conclusion/implications	
MBLs were readily detectable in the gut flora of the sampled zoo animals, including 
previously unknown ones, even though relatively selective methodology was applied. Their 
presence in gut commensals/opportunists should reduce some barriers for transfer to 
pathogens. Next step is to sequence the isolates to gain knowledge about mobility and 
possibly origin of the novel carbapenemase genes found. 1.5 Key	words:	
Antibiotic resistance, Carbapenemases, Metallo-β-lactamases, Resistome  
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2 Background	
2.1 The	threat	of	antibiotic	resistance	
Modern medicine is by large depending on effective antibiotics. Apart from treating primary 
bacterial infections, antibiotics enable other treatments and therapies, e.g. transplants, surgery, 
immunotherapy and cancer treatment. But many of our historically successful antibiotics have 
been lost due to antibiotic resistance. An estimated 700 000 lives are claimed annually due to 
antimicrobial-resistant infections alone. 1-3 
	
Multi-resistant bacteria and especially the extended spectrum β-lactamase producing bacteria, 
(ESBL) are considered a grave threat to the public health. The ESBLs are capable of disabling 
almost all of the β-lactam antibiotics – the most common family of antibiotics in use. Our last 
resort to combat the ESBLs and many of the other multi-resistant bacteria is often the 
carbapenems, the most potent antibiotic with the broadest spectrum against Gram-positive and 
Gram-negative bacteria discovered. 2 However, certain pathogens (Carbapenemase-producing 
Enterobacteriaceae, in Sweden called ESBLCARBA) have acquired carbapenemase activity and 
can, as it name implies, hydrolyze carbapenems, which only leave us with drugs like colistin, 
tigecycline, and fosfomycin as our remaining options. Alternatives that are subject to their 
own resistance problems and have a high mortality rate and severe side effects (renal and liver 
toxicity, etc.). 4,5,6 
 
To guide resources to research, discovery and development of new therapies WHO, in 
September 2017, published a Global priority list of antibiotic resistant bacteria. The highest 
priority group (Critical) were all carbapenem-resistant strains, underlining the threat they 
pose7. 
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 A	brief	history	of	antibiotic	resistance	
Antibiotic molecules have existed long before humans discovered, named and started mass-
producing them. For as long as there has been competition between microbes, there has also 
been a role for defensive countermeasures in these constant ongoing inter-microbial conflicts 
and it’s not surprising that even in the most pristine environment thinkable, like 30 000-year-
old Beringian permafrost sediments, antibiotic resistance genes have been found.8,9  
 
The antibiotic resistance genes in environmental bacteria are known as the environmental 
resistome. There is growing evidence that this resistome acts as a huge source of genes from 
which human pathogens can acquire novel resistance determinants. This process, which most 
likely involve multiple steps, could be facilitated in the presence of a selection pressure from 
antibiotics.10 It is likely that the increased consumption of antibiotics eventually leads to an 
increased concentration of antibiotics in the environment that speeds up the aforementioned 
process. The consumption of antibiotic drugs has increased by 36% globally between 2000 
and 2010, and between 2010 and 2030 it is estimated to increase with another 67% to 105 000 
tons per year.11,12 
 
 Acquisition	of	antibiotic	resistance	
There are two main mechanisms for a bacterium to acquire resistant genes: mutations and 
horizontal gene transfer (HGT): 
Mutations in the DNA can either alter the molecular structure of the target site, reducing the 
affinity of the antibiotic molecule and thus reducing/eliminating the effect of the drug, or alter 
other important structures that can reduce the efficacy of the drug, such as the gene expression 
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of efflux pumps, or alter the number or structure of porins. Mutations tend to occur slowly 
and randomly. 
HGT is usually divided into three subgroups: 
Conjugation – where the host bacteria creates pilus that attaches to target bacteria and through 
which plasmids can be transferred.  
Transformation – where the bacteria binds to DNA in the extracellular environment and 
engulfs it and incorporates it into the bacterial DNA. 
Transduction – or bacteriophage – a virus containing antibiotic resistance gene DNA infests a 
bacteria and DNA is incorporated into the DNA of the target bacteria. 13 
 2.2 Carbapenems	
 History	of	carbapenem	
Carbapenems are a subgroup of the β-lactam family of antibiotics. The carbapenems are more 
resistant to enzymatic hydrolysis compared to other beta-lactams. Carbapenems were 
discovered roughly 50 years ago, but it took 20 years before the first drug was out on the 
market. 14,15 The parent compound for carbapenem antibiotics was the potent β-lactam 
thienamycin, a molecule produced by the soil bacteria Streptomyces cattleya. Unfortunately, 
thienamycin was too unstable to be used in vivo, but minor changes to the structure resulted in 
the more stable and commercially viable imipenem being launched in 1985 16,17. Imipenem’s 
effect is reduced by renal dihydropeptidase (DHP-1) but today DHP-1-resistant variants have 
been launched like meropenem (1996), ertapenem (2001), and doripenem (2007). 7,18,19 
Unlike the other carbapenems, meropenem can pass the blood-brain barrier to treat CNS 
infections if dosed in high enough concentrations. 20 
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 Carbapenems	antibiotic	action	
The integrity of the bacterial cell wall is of essential importance for the bacteria and provides 
structure, stability, and form to the bacteria. The cell wall is autolyzed and synthesized by the 
bacteria’s own machinery. One of the indispensable components for synthesis is the cross-
linking of the peptidoglycan that stabilizes the bacterial cell wall. The cross-linking is 
performed by the enzyme PBP (penicillin-binding protein). PBP binds to a terminal alanine 
on one peptidoglycan chain and forces out an alanine on a peptidoglycan chain next to it and 
forms a link between the two chains. 21,22 
 
Carbapenems share the same fundamental mechanism as all β-lactams by acting as an analog 
to the terminal alanine, which makes the PBP bind irreversibly to the carbapenem thus 
inactivating the PBP and preventing it from cross-linking the peptidoglycan layer which in 
turn halts the cell wall synthesis. β-lactams have also been shown to increase the expression 
of autolysin which degrades the cell wall, and together with the decreased synthesis, β-
lactams weakens cell wall integrity and makes the bacteria’s internal osmotic pressure rupture 
the cell wall. The combination of these mechanisms makes β-lactams bactericidal. 23 
 
 Carbapenems	clinical	importance	
Carbapenems are in Sweden used for patients above 3 months of age with severe and 
complicated bacterial infections where the pathogen and susceptibility is unknown. The only 
real contraindication is hypersensibility to β-lactams.24 
 
As a group, carbapenems have proven to be effective against many of our most aggressive 
pathogens: Staphylococcus aureus (incl those with penicillinase activity), Enterococcus spp, 
Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus viridans, Acinetobacter 
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spp, Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, 
Pseudomonas aeruginosa, etc.22 
 2.3 Carbapenem	resistance	
 Mechanisms	of	carbapenem	resistance	
There are four known mechanism for carbapenem resistance in bacteria:  
Porins – β-lactams like carbapenems cannot penetrate the cell wall of the gram-negative 
bacteria. Instead, they use the porins to enter the bacteria. The bacteria can either reduce the 
expression of porins or alter the structure of the porins, making them more selective, both of 
them reducing cell wall permeability. 22,25-27 
 
Efflux pumps – The bacteria have efflux pumps of varying selectivity integrated into the cell 
membrane that allows them to pump out potentially harmful molecules and ions. 
Carbapenems are mostly affected by the broad specificity efflux pumps (multidrug-resistant 
efflux pumps – MDR). Overexpression of efflux genes is often the result of mutations.22,25,26 
 
Penicillin-binding proteins with poor affinity to carbapenems (PBP) – Some resistant 
bacteria (gram-positive Enterococcus spp. among others) downregulates a majority of their 
regular PBPs and upregulates or acquires modified PBPs with an altered structure that makes 
it difficult for carbapenems to bind and have its effect.22,28  
 
Carbapenemases – hydrolyzes the β-lactam ring of the antibiotic which inactivates the 
molecule. Genes encoding carbapenemases can be found on both chromosomes and plasmids. 
The origin of the β-lactamases has been speculated to be mutated PBPs.22,25,26  
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Apart from the known mechanisms above there is also the carbapenem intrinsic resistance 
(CIR) e.g. CarF and CarG proteins, produced by carbapenem-producing subgroups of the 
Erwinia, Photothabdus and Serratia species. Function and mechanism are unknown.29 
 
 Cost	of	carbapenem	resistance	
All biological activities come with a price tag for the organism. The expression of antibiotic-
resistant genes is no exception. Carbapenem-resistant bacteria will have an obvious advantage 
in carbapenem-rich environments. Conversely, in an environment without the antibiotic 
pressure, ceteris paribus, a susceptible bacteria not carrying the overheads related to the 
resistance genes will outpace the growth of the resistant bacteria.30  
 
In vivo, the actual cost for the resistant genes is also depending on co-selection and 
compensatory evolution. If the specific carbapenem resistance gene is selected together with 
other genes that are beneficial for the survival of the host, the fitness cost for the carbapenem-
resistant gene will be balanced by the gain of the bundled genes. Compensatory mutations can 
over time reduce the fitness cost of the carbapenem resistance gene making them less costly. 
Modified versions of the produced enzymes can also turn out to have other benefits for the 
host that in turn compensates the original fitness cost.31,32 
 2.4 Carbapenemases	
Two possible functions that can explain the evolution of carbapenemases have been proposed: 
to defend the integrity of the cell wall from the toxic effect of carbapenem-like molecules 
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produced by themselves or other microbes, and as an important protein to balance and recycle 
the peptidoglycan layer in the cell wall.21 
 
β-lactamases is commonly divided into Ambler class A, B, C or D depending on amino acid 
homology. Three, A, B and D, of the classes contain carbapenemases that are clinically 
relevant. 
 
Ambler class A and D have a conserved serine in the active site that mediates the hydrolysis 
of the β-lactam ring. 33 Members of the Ambler class B, also known as Metallo-β-lactamases 
(MBL), have metallic ions (often zinc) in their active sites. The ions, usually a pair of zinc 
ions, position a water molecule that activates and hydrolyzes the N-C bond. 33,34. A way to 
clinically distinguish between serine- and metallo-β-lactamases is by adding the metal 
chelating agent ethylenediaminetetraacetic acid (EDTA) which inactivates the zink and 
thereby inhibit MBLs, but not the serine-β-lactamases.35,36 
 
                
Source: https://commons.wikimedia.org/wiki/	File:Carbapenem.svg (modified) 
Figure 1 -  Carbapenemases target structure. Carbapenemases hydrolyzes the 
carbapenems C-N bond, weakening the structure of the β-lactam ring. 
 
 Ambler	class	A	
Class A β-lactamases hydrolyzes penicillin, cephalosporins, and carbapenems. They are 
partially or fully inhibited by clavulanic acid or tazobactams. They fall phylogenetically into 
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five groups: KPC (Klebsiella Pneumoniae Carbapenemase), IMI (Imipenem-hydrolyzing β-
lactamase), GES (Guiana Extended-Spectrum β-lactamase), NMC (Not Metalloenzyme 
Carbapenemase), and SME (Serratia Marcescens Extended-spectrum β-lactamase). 37,38 
 
Class A carbapenemase genes can be chromosomal, often as gene cassettes in class 1 
integrons. But they can also be part of transposable elements on plasmids.39 The class A 
carbapenemases are most frequently found in Enterobacteriaceae and P. aeruginosa. 37,38 
 
 Ambler	class	B	–	Metallo-β-lactamases	
Metallo-β-lactamases (MBL) are considered a major challenge to the public health.40 They 
can hydrolyze all beta-lactams, excluding aztreonam, and are often co-selected with other 
resistance genes making the host pan-resistant. The MBLs can appear both on chromosomes 
and plasmids. They are known to disseminate rapidly between bacterial strains as well as 
continents.41,42 The MBLs are not inhibited by clavulanic acid or tazobactam but they do show 
inhibition when exposed to metal chelators like EDTA36. The most widely distributed among 
pathogens are the NDM (New Delhi metallo-β-lactamase), IMP (Imipenemresistance), and 
VIM (Verona integron-encoded metallo-β-lactamase). 
 
Important pathogens that will express the MBLs include E. coli, P. aeruginosa, K. 
pneumoniae, A. baumannii, all quite common in the clinical setting.35,43 The MBLs are 
classified into three groups, B1-B3. Among the MBLs the, by far, most identified type is the 
B1. B1 and B3 have a broader resistance spectrum and have two zinc ions in the active site, 
whereas the B2 only have one.44,45 
 
  
 
11 
 Ambler	class	D	-	Oxcillinases	
Class D β-lactamases are commonly known as the Oxacillinases (OXA) due to their 
hydrolytic activity for cloxacillin and oxacillin. The OXA types include more than 400 
enzymes, but the most likely subgroups to cause concern are enzymes that can be found in 
bacterial pathogens and can hydrolyze carbapenems.46,47. A majority of the OXA enzymes 
have been identified in Acinetobacter spp, but some OXAs, like the OXA-48, have also be 
found in K. pneumoniae, P. Aeruginosa as well as E. coli.38,47 
 2.5 Spreading	mechanisms	of	carbapenemases	
The expression and the spreading pattern of a carbapenemase gene is affected by the location 
of the gene, chromosomal DNA or plasmid, and the surrounding regions.  
 
The chromosomal DNA contains all the information needed for the bacteria’s essential 
household protein synthesis. Since the chromosomal DNA is essential for the basic functions 
and thus the survival of the bacteria, any changes to the chromosomal DNA comes with a 
higher risk for the bacteria.  
 
Carbapenemases spread predominately through plasmids, which in comparison to the 
chromosomes are smaller and contains fewer genes. Genes on plasmid can help bacteria to 
better survive environmental factors, deal with high concentrations of substances that might 
be harmful, like metals or antibiotics, to outcompete other bacteria, to kill off other bacteria 
etc. Plasmids can be picked up, ejected and transferred to other bacteria. 48 
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2.6 Where	do	carbapenemases	come	from?	
Tim Walsh sampled New Delhi water sources and found that bacteria from 166 out of 171 
seepage samples and 14 out of 50 tap water samples grew on mereopenem supplemented agar 
plates, suggestive of carbapenemase activity. Two of the water samples and 51 of the seepage 
samples were positive for NDM-1. In total 20 different bacterial strains were found carrying 
the NDM-1, including species like Shigella boydii, Vibrio cholera, E. coli, P. aerguinosa and 
a K. pneumoniae but also strains like Sutonella indologenes, Stenotrophomonas maltophilia, 
Achromobacter spp, Kingella denitrificans and other Pseudomonas spp. NDM-1 is frequently 
found in clinical samples in India, but the study showed that it is also common in the 
environment. 49 
 
Environmental bacteria can thus serve as a source of carbapenemases (and other resistance 
genes) that under the right circumstances can be transferred to pathogenic bacteria. Members 
of the Shewanella genus, a family of gram-negative bacillus found in marine and freshwater 
environments, have been suggested to carry the progenitors of numerous β-lactamases and 
quinolone resistance genes found in pathogens today. The chromosome of Shewanella 
xiamenensis is likely the origin of the OXA-181 gene (a class D carbapenemase), identified 
on plasmids of several bacterial species, including common pathogens like Klebsiella 
pneumoniae and Enterobacter cloacae. Based on the similarity (only 4 amino acids differ) 
and the nucleotide sequences next to the genes it is also highly likely that the S. xiamenensis 
OXA-181 gene is the origin of OXA-48 gene. The plasmid-harboured OXA-48 is spreading 
into many enterobacterial species and caused numerous hospital outbreaks of carbapenemase-
producing Enterobacteriacae.50 
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Another example of genes moving from the chromosome of an environmental bacterial to the 
plasmid of pathogenic bacteria is the commensal Acinetobacter radioresistens that has found 
to be the source of the chromosomal OXA-23 gene that can be found on plasmids of the 
substantially more virulent Acinetobacter baumannii.51  
 
With this in mind the mobility of carbapenemase genes from environmental bacteria to 
pathogens, is a threat to be taken seriously. By identifying the environmental carbapenemases 
we stand prepared if they show up in the clinic, enabling us to the take right course of action.  
 2.7 Barriers	for	genetic	migration	
One can argue for two barriers preventing genes in environmental bacteria to migrate into 
pathogens: the genetic and the ecological.52  
 
Genetic – If the genes are chromosomal and not associated with mobile elements, or if they 
are mobile but require specific cellular machinery that is not compatible with pathogens, there 
is less probability of successful migration.  
 
Ecologic – If the genes flourish in a certain bacterial species that thrives in an environment far 
from what the pathogens can survive in, it is less likely for the genes to get a possibility to 
migrate to the pathogens.  
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3 Aim	
With the long-term goal to protect the public health, it is important that we identify as many 
carbapenemases as possible to be able to screen for it in the clinic but also to understand how, 
where and when the carbapenem resistance emerges and spreads. 
 
” What this implies is that for any antibiotic used in medicine or agriculture, the spectrum of resistance 
elements in the environment must be cataloged and monitored for possible mobilization to the clinic. Such 
studies will provide an early warning system for the predictable development of resistance in pathogens.”  
Waglechner and Wright 53 
 
By considering barriers for genetic migration and collecting samples from an environment 
similar to that in and on the human body, we increase our chances of identifying genes that 
eventually might end up in human pathogens. We can achieve this by sampling the microbiota 
of the gut of animals, an environment not only similar to ours, but also rich in bacteria and 
nutrients, with a high potential of gene sharing between bacteria. Animal stool samples are the 
simplest way to study their gut microbiota.  
 
 Purpose	
The purpose of this project is to explore the environment for novel carbapenemases, to find 
the gene before it finds the pathogen. The project is part of a bigger framework – NoCURE - 
headed by Professor Joakim Larsson with the aim to discover emerging novel 
carbapenemases, define modes of mobility and assess the potential of these carbapenemases 
to spread to human pathogens, so that we might know what we will be up against before they 
become a real threat to us.  
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 Research	question	
Can we find novel carbapenemases in the stool of animals never deliberately exposed to 
carbapenems? If yes, what characteristics would they have and what Ambler class would they 
belong to? What bacterial species would host these novel carbapenemases and would the 
genes have the capacity to transfer to known human pathogens? Which animal would be 
colonized with these carbapenemase-producing bacteria?  
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4 Material	and	Methods		
4.1 Setting	
Being an explorative study, we wanted the animal population to be as diverse as possible. We 
also wanted to make sure we had a somewhat controlled environment in order to reduce 
contamination from other species and to allow us, in case we found carbapenemase-producing 
bacteria, to identify what animal species was colonized by the bacteria. The obvious solution 
was a zoo. We contacted Nordens Ark, a zoo specializing in the preservation of endangered 
species 90 km north of Gothenburg. They were very supportive of the idea and agreed to get 
the samples we needed per our instructions.  4.2 Sampling		
Out of the roughly 80 species at Nordens Ark Zoo we chose 43 species that would provide us 
with sufficient sample volume, a good variation and a good coverage of the mammals as well 
as birds and amphibians (see 13 Appendix A: Nordens ark - Species). 
 
The 43 stool samples were collected by the animal keepers of Nordens Ark. We supplied 
buckets containing disposable gloves, tubes, ethanol, spoons, paper towels and instructions 
that stated the samples should be taken with a disinfected spoon, the feces should be fresh, 
samples should only contain fecal material, store the samples on ice, and that it was 
acceptable to pool from two or more stools from the same species to get enough material (see 
Appendix B for full instructions).  
 
The samples were collected in 50 ml tubes and put on ice immediately after sampling. All 
samples were collected within three consecutive days and were inoculated on the fourth day. 	
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4.3 Preparation:	Inoculation	and	selective	culturing	
To promote as many different species of gram-negative bacteria as possible three different 
nutrient broths were used: 
 
Tryptic soy broth (TSB) High nutrient general purpose broth suitable for most bacteria 
but favors fast-growing ones. 
R2A Low nutrient broth, allow of also slow-growing bacteria 
MacConkey Promoting gram-negative and enteric bacteria like E. coli. 
Gram-positive bacteria are inhibited by the bile salts and 
crystal violet. 
 
The following selective agents were added: 
Cyclohexamide (100 mg/l) that inhibited translocation of tRNA and mRNA progression in 
eukaryotic cells (to inhibit growth of fungi).  
Vancomycin (10 mg/l) that effectively inhibits growth of gram-positive bacteria, as some 
common enteric gram-positive bacteria are intrinsically carbapenem-resistant, like the 
Enterococcus spp, allowing them to grow unhindered and thereby disturbing the selective 
process. The gram-negative bacteria are resistant to vancomycin.  
ZnSO4 (70 micromoles) provides additional zinc to promote the activity of MBLs. 
Meropenem to enrich for carbapenemase-producing bacteria. The broths contained three 
different levels of concentration of meropenem (0, 0.25, 4 mg/l). 
 
Approximately 1 ml feces sample was mixed with 2 ml physiological NaCl and vortexed into 
a solution. 100µl of the suspension was added to 5 ml broth in 10 ml tubes. The broth acts as a 
nutrient and a selective agent (depending on meropenem concentration) for the sample. The 
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resulting 387 (43 species * 3 broth types * 3 meropenem concentrations) tubes were marked 
with assigned animal-number and broth type and meropenem content.  
 
The tubes were stored on a platform rocker at 30C at 150 rpm until there was visible proof of 
growth compared to a non-inoculated media (23 hours for the broths without meropenem 
supplementation and 48 to 92 hours for the supplemented ones). All samples were sorted and 
the tubes were marked with growth and no growth.  
 
1 ml from each tube was pooled together within the same animal group (Mammals A, 
Mammals B, Birds, Amphibians, Farm animals) and meropenem concentration. All sample 
tubes were topped off with glycerol and put in a -80C freezer. 
	
 
Figure 2 - Broth inoculation variants. R2A, TSB and MacConkey with three 
different concentrations of meropenem. 
 
After the cultivating in selective broth and creating pools a number of methods were applied 
with the aim to identify novel carbapenemases (Figure 3 - Methods used). 
Stool	sample
R2A	broth
0	mg/L	Meropenem
Shotgun	pool	1
0,25	mg/L	Meropenem
Shotgun	pool	2
4	mg/L	Meropenem
Shotgun	pool	3
TSB	broth
0	mg/L	Meropenem
Shotgun	pool	4
0,25	mg/L	Meropenem
Shotgun	pool	5
4	mg/L	Meropenem
Shotgun	pool	6
MacConkey
0	mg/L	Meropenem
Shotgun	pool	7
0,25	mg/L	Meropenem
Shotgun	pool	8
4	mg/L	Meropenem
Shotgun	pool	9
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Figure 3 - Methods used. For the subsequent methods used the source material was 
either resistant isolates or pooled genome. 
 4.4 Isolates	
A 10 µl inoculation loop of the broth tubes with added meropenem showing growth were 
streaked out on meropenem-supplemented agar plates of the same media type used in the 
broth (R2A, Tryptic Soy or MacConkey). The plates were incubated for approximately 2 days 
at room temperature until visible growth was seen.  
 
 Carba	NP	test	on	bacterial	isolates	
Carba NP is a simple and robust test, measuring the actual performance of the bacteria. The 
test takes advantage of the pH drop that occurs when carbapenemase hydrolyzes carbapenem 
(imipenem in this case) the drop can be visualized by using the pH-indicator phenol red.  
 
Solution A was prepared by mixing 0.15g phenol red (Sigma, St. Louis, MO, USA) with 30 
ml of dH2O and adding 249 ml of H2O and 2.7 ml of 10 mM ZnSO4. 
 
For each strain to be tested, one tube with 100 µl of Solution A (negative control) and one 
tube with 100 µl solution A with an Imipenem concentration of 12 mg/ml were prepared. Two 
Cultivate	samples	in	meropenem	selective	broth
Isolate	resistant	colonies
Maldi-TOF	to	identify	species
Carba	NP	test	for	carbapenemaseconfirmation EDTA-test	to	check	for	MBLs
Pool	according	to	meropenem	concentration	and	broth	type Shotgun	sequencing Hidden	Markov	Model	(HHM)	for	novel	genes PCR	to	find	genes	in	isolates PCR	to	find	genes	in	animal	pools
Functional	metagenomics
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10 µl inoculation loops of bacteria were collected from Mueller-Hilton agar plates and added 
to 200 µl of B-PER II lysis buffer (Fisher Scientific, Rockford, IL). The mixture was vortexed 
for 1 min and left in room temperature for 30 min. The samples were then centrifuged for 5 
min at 10 000 g before 30 µl of supernatant was added to tubes containing Solution A and 
Solution A + Imipenem. The tubes were incubated at 37 °C and examined after 15, 30 and 60 
min. Bacterial strains expressing OXA-48, VIM-2, and KPC-2 were used as positive controls. 
 
 Imipenem-EDTA	synergy	test		
MBLs need zinc in their active site to hydrolyze the β-lactams. The presence of a zinc 
chelator like EDTA will inhibit the action of the MBLs. To test for presence of MBLs in the 
collected isolates, Mueller-Hinton agar plates were inoculated evenly with the bacterial strains 
before a strip with a gradient of imipenem in one end and a gradient of imipenem + a fixed 
concentration of EDTA in the other end were placed onto the inoculated agar surfaces. The 
plates were incubated for 24h at 37 °C before being assessed. If bacteria-free zone on the 
EDTA + imipenem side was significantly larger than on the imipenem-only side the test was 
interpreted as positive (indicating a presence of a MBL in the isolate). 
 
 Maldi-TOF	
Matrix-assisted laser desorption/ionization – Time of Flight mass spectrometer (Maldi-TOF) 
is a technique to analyze DNA, proteins, peptides, sugars, and macromolecules through laser 
ionization and mass spectrometry. Maldi-TOF was used to determine the species of the 31 
collected isolates based on the mass spectrometry readings of the ionized substances. The 
readings were matched against the clinical MYLA database, and for isolates not matched, the 
research-oriented Saramis database was used as a complement. 
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4.5 Functional	metagenomics	
 DNA	extraction	and	preparation	of	libraries		
The inoculated tubes with broths showing growth were pooled according to the three media 
types and the three meropenem concentrations, nine pools in total. For the shotgun 
sequencing, functional metagenomics and PCR bacterial DNA was extracted from the pools. 
The Qiagen DNeasy standard protocol was used to prepare the bacterial DNA. The yield of 
the extracted DNA was measured by Qubit Fluorometer 2.0.   
 
 Functional	metagenomics	test	
From the extracted DNA libraries were prepared using the pZE21-MCS vector (Expressys, 
Germany) following the protocol designed by Sommer, et al. 54 Through electropermeabiliza-
tion the prepared metagenomic library was introduced into NEB 10-beta electrocompetent E. 
coli (New England Biolabs, MA, USA). 
 
Source: Moore 55(2011) 
Figure 4 - Creating vectors in E. coli for functional metagenomics After DNA is 
extracted cloning vectors are created that is then picked up through transformation 
by competent E. coli. E. coli with vectors can potentially express the genes of 
interest and through selective cultivation and PCR the necessary amount of those 
genes can be produced and sent for sequencing. 
  
 
In order to select for carbapenemase-producing E. coli, all vector-infused E. coli were 
cultivated on meropenem enriched plates of the same type as the broth (R2A, Tryptic soy, 
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MacConkey). Growth in presence of meropenem would then indicate cloning a functional 
expression of a carbapenemase gene in the E. coli strain. When the E. coli has acquired 
resistance and the functional screening is done, the amount of DNA to sequence is only a 
fraction of that of the whole sample genome. Thus, the rationale of using functional 
metagenomics is to filter out junk DNA to be able to focus the sequencing and assembly 
resources on the relevant DNA sequences. If the functional metagenomics doesn’t provide 
any result, an alternative is to run other functional tests like Carba NP and EDTA on the 
isolates. 
 
 Metagenomic	sequencing		
The same DNA pools used for functional metagenomics were sent for shotgun sequencing 
with Illumina HiSeq at National Genomics Infrastructure (NGI) in the national center Science 
for Life Laboratory (scilifelab.se) in Stockholm.  
 
 BLAST	and	hidden	Markov	model	
The HiSeq output was assembled and analyzed by Fanny Berglund, member of Erik 
Kristianssons research group at Chalmers Bioinformatics.  SPAdes (St Petersburg genome 
Assembler) was utilized for the assembly and sequences were matched to the BLAST 
database for known genes. For detection of novel MBL B1 and B3 type genes, newly 
developed hidden Markov models were applied.56 As suggested by Cornaglia et al. a gene was 
considered novel if it displayed less the 70% amino acid sequence identity to known MBLs.57  
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4.6 Finding	novel	sequences	in	samples	through	PCR	
Protein sequences identified in the Hidden Markov model were aligned to a longer series of 
nucleotide sequences retrieved from the HiSeq sequencing. Based on the aligned sequences, 
we used NCBIs primer tool (https://www.ncbi.nlm.nih.gov/tools/primer-blast) to design 
primers. Default settings were used except the PCR product length were set to be above 100 
base pairs to get at clear separation from any primer dimers (located below 100 base pairs) 
and the taxa to crosscheck for alternative targets were Animalia (taxid:33208) instead of the 
default: Homo Sapiens. Designed PCR primers were ordered online from Eurofin.  
 
 PCR	settings	
PCR kit used was Applied biosystems AmpliTAQ (Foster City, California). No enhancer was 
used. For each run, a master mix was created and then primers and DNA were added 
separately. The reaction volume was 25,125 µl and consisted of 15 µl distilled water, 2,5 µl 
PCR Buffer, 2,5 µl MgCl2, 2 µl dNTP, 0.125 µl of Taq polymerase, 1 µl of forward primer, 1 
µl of reverse primer and 1 µl of DNA. 
 
The thermoblock program was set to initial denaturing at 94 °C for 3 min, followed by 39 
cycles of denaturing at 94 °C for 30 seconds, annealing temperature (between 56-59 °C) for 
30 seconds, elongation at 72 °C for 15-35 seconds and last cycle ended with a final elongation 
of 72 °C for 7 minutes and the cooldown program was set to 10 °C indefinitely. The 
annealing temperature was decided by taking the primer’s estimated melting temperatures 
(estimation by primer supplier Eurofin) and subtracting 3 °C. If the gel showed a lot of 
unspecific products, the PCR program was adjusted by increasing the annealing temperature. 
The elongation time in each cycle based on the length of the expected PCR product (between 
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100-500 base pairs) and the approximation that the polymerase should manage 1000 base 
pairs per minute.  
 
 PCR	pools	and	isolates	
To find the 19 novel genes among the 31 isolates and 43 animals samples the DNA was 
pooled for the first screening. The isolates were pooled according to broth media and 
meropenem concentration (label in parenthesis): R2A 0,25 mg/l (2), R2A 4 mg/l (3), TSB 
0,25 mg/l (5), TSB 4 mg/l (6). The animal samples were pooled based on the groups: 
Mammal 1 (A), Mammal 2 (B), Birds (C), Amphibian (D) and Farm animals (E) (see 
Appendix A: Nordens ark - Species). For each novel carbapenemases gene, a total of 9 sample 
pools (2, 3, 5, 6, A, B, C, D, E) and positive controls and negative controls (without any 
DNA) were screened.  
 
As a positive control we initially pooled all extracted DNA from one media, TSB with 0,25 
mg/l meropenem (labeled +). After a couple of runs and some missing positive control bands, 
the remaining three combinations of meropenem concentrations (TSB 4 mg/l, R2A 0.25 mg/l, 
R2A 4mg/l) and broths were to create a second positive control (labeled ++).  
 
When a positive result was retrieved from a pool, the same primer pairs and procedure were 
applied to find the individual isolate/isolates positive for the detected novel carbapenemase 
genes. 
 
 Agarose	Gel	setup		
The PCR products were visualized by running them on a 1 % agarose gel stained with 
SYBRsafe. 
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7,5 µl of PCR reaction was mixed with approx. 2 µl of loading dye and then loaded into the 
wells. The DNA ladder 1 kb+ (Thermo-Fischer) was used as size reference. The gel was run 
over 40-45 minutes at 90 volts and moved to a UV-lightbox and a photo was taken.  
 
A dominating band at the right length (and thus the same length as the positive control) in the 
gel was considered a positive finding. If results were ambiguous, the PCR was rerun at a 
couple of degrees higher annealing temperature. If still uncertain the screening was continued 
with the next primer pair. 
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5 Ethics	
Animal stool samples collected from a forest setting would from an ethical point of view be 
quite straightforward. Samples picked from the environment with no relation to the former 
host animal, they could be considered environmental samples and then no ethics approval is 
needed.  
 
The ethical considerations of our samples from enclosed animals are slightly more complex. 
On one hand, it partly follows the environmental rationale above, but to a larger extent it also 
affects the animal in question as collecting samples would require the keepers to enter the 
enclosed area possibly stressing the animal. In addition, the fecal samples can be traced back 
to the animal, giving it a certain ownership of the stool. The latter is important when handling 
human samples as stated in the Swedish law (in Etikprövningslagen) that makes a clear 
distinction between the aggregated fecal sampling (eg. from sewage samples) that doesn’t 
require permission and the sampling involving biologic matter that can be traced to that 
person that requires an ethics permission. Out of the 3Rs commonly used in animal research 
(Replacement, Reduction and Refinement), only Refinement is really applicable and the way 
for us to refine is to lower the stress of the animal by just adding the fecal sampling to the 
keepers’ everyday routine.58 
 
In the case of the enclosed animal, we also have the owners’ perspective to consider. If we 
find carbapenemases, will it harm their business or change how the animals are treated or 
viewed by the public?  
 
After considering all the aspects and laws governing the area, we came to the conclusion that 
an ethical permit was not mandatory as long as we had the blessing and support of the Zoo. 
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The additional stress would be minimal as the fecal sampling are mainly done by the animal 
keepers whilst feeding the animals. The rules regarding identification as mentioned above are 
not really applicable to animals and any theoretical ethical dilemma diminishes compared to 
the benefit of being able to identify the animal as it would enable us to go back to that animal 
for a later study and see if carbapenemase-producing bacteria are still colonizing the gut flora. 
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6 Results	
6.1 Collection	of	31	meropenem	resistant	isolates	of	mainly	opportunistic	bacteria	originating	from	animal	feces	
Tubes showing growth in the meropenem supplemented broth were streaked on plates, and 
colonies with different appearances on the plates were picked, in total 31 isolates were 
collected, given an ID number and frozen -80 °C in glycerol. Out of the 31 isolates, 21 could 
be properly identified with Maldi-TOF using the MYLA database as reference. A majority of 
the identified species are known opportunistic pathogens (Table 1). 
Table	1:	Bacterial	strain	identification	with	Maldi-TOF.	
 
Bacterial species within parenthesis were not identified by MYLA, data from the 
Seramis database was used instead. Only species with multiple documented human 
infections were considered opportunistic.59-66  
 
Since the isolates had managed to grow in meropenem they must have had some active 
resistance mechanism, either intrinsic resistance, porins, efflux pumps, modified PBPs or 
ID MYLA (Seramis) Opportunistic
21 Stenotropomonas maltophilia Yes
22 -
23 Sphingobacterium multivorum Yes
24 Comamonas testosteroni Yes
25 (Trichosporon asahii) (Yes)
26 Sphingobacterium multivorum Yes
27 Pseudomonas veronii No
28 Sphingobacterium multivorum Yes
29 -
210 Stenotropomonas maltophilia Yes
211 Empedobacter brevis Yes
212 Sphingobacterium multivorum Yes
30 Chryseobacterium indologenes Yes
31 Stenotropomonas maltophilia Yes
32 (Trichosporon asahii) (Yes)
33 (Chryseobacterium spp.) (Yes)
34 Leuconostoc mesenteroides Yes
35 Stenotropomonas maltophilia Yes
36 Chryseobacterium indologenes Yes
37 Elizabethkingia meningoseptica Yes
51 Streptococcus pluranimalium No
53 -
54 -
56 Pediococcus pentosaceus No
57 -
58 Leuconostoc mesenteroides Yes
59 Pseudomonas veronii No
61 -
62 Leuconostoc mesenteroides Yes
63 -
64 Leuconostoc mesenteroides Yes
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carbapenemases. There was growth in some MacConkey broth but no colonies grew on the 
subsequent MacConkey plates.  
 
It is worth nothing that two of the isolates (number 25 and 32) were identified as 
Trichosporon Ashii, a fungi that should not be able to survive the cyclohexamide in the 
broths. Isolate number 32 was also positive in the Carba NP and imipenem-EDTA synergy 
tests indicating MBL production. 
 6.2 Carba	NP	showed	carbapenemase	activity	in	collected	isolates	
The Carba NP test was performed on the 31 collected isolates. For some slow-growing 
isolates, there were difficulties getting enough colonies to do the Carba NP test. However, 17 
out of the 31 isolates (that was identified with MALDI-TOF) gave rise to a color change from 
red to yellow in the test as a result of the hydrolyzation of imipenem, an indication that the 
reason they survived the meropenem plates was at least partly due to carbapenemase 
production (Figure 5). 
 
Figure 5 - Carba NP test. The photo shows 14 out of the 17 positive Carba NP 
tests. , VIM-1, KPC-2, OXA-48 served as positive controls whereas TEM and AMpc 
served as negative controls  
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6.3 All	Carba	NP	positive	isolates	were	also	MBL-positive	
Out of the 17 isolates that were positive with the Carba NP test all were clearly positive in the 
imipenem-EDTA synergy test, which suggest MBL activity (Figure 6). The three slow-
growing isolates on which Carba NP could not be performed, also showed positive results in 
the imipenem-EDTA synergy test. In the latter cases, there was some suspicion of 
contamination and those findings therefore need to be confirmed by additional tests. 
 
Figure 6 – Imipenem-EDTA synergy test. Representative photo of an isolate 
showing a positive result in the imipenem-EDTA synergy test. The upper part of the 
stick contain imipenem + EDTA whereas the lower half of the stick contains 
imipenem alone. The EDTA test showing growth inhibition near the 
EDTA+Imipenem part of the strip. 
 6.4 No	E.	coli	hosts	survived	on	the	selective	plates	during	the	functional	metagenomics	screening	
For the functional metagenomics, all of the initial broths showing growth were pooled 
according to the three media types and the three meropenem concentrations, creating nine 
pools in total. Vector-infused E. coli were cultivated on meropenem-enriched plates of the 
same type as the broth. Growth would then indicate a functional expression of a 
carbapenemase gene, but none of the E. coli hosts survived the selective meropenem plates 
and thus there were no subjects available to send for sequencing.  
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6.5 Novel	B1	and	B3	genes	found	by	shotgun	sequencing	and	hidden	Markov	model		
The same nine pools were used for the shotgun sequencing as for the functional 
metagenomics above. After shotgun sequencing and assembly, the hidden Markov models 
identified several novel MBLs in sequences longer than 200 amino acids, 13 sequences of B1 
type and 6 sequences of B3 type. These corresponding nucleotide sequences were then used to 
design primers for PCR. 
 6.6 6	novel	B1	genes	found	in	the	isolates		
Through PCR 6 of the 13 novel B1 genes could be linked to specific isolates (Figure 7). Gene 
36 and 42 were found in isolate number 29 (unidentified). Gene 2 and 31 were found in 
isolate 51 (Streptococcus Pluranimalium). Gene 41 was found in isolate 61 (unidentified) and 
isolate 63 (unidentified). Gene 42 and 73 were found in isolates 33 (tentatively matched as 
Chryseobacterium spp. ) and 34 (Leuconostoc Mesenteroides).  
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Figure 7 – Novel MBL B1 genes detected in isolates by PCR. A) Gene 36 & 42 
found in isolate 29 B) Gene 2 & 31 found in isolate 51 and gene 41 found in isolate 
61 & 63 C) B1: Gene 42 & 73 found in isolate 33 & 34 
 6.7 3	novel	B3	genes	found	in	the	isolates			
For the novel B3 genes, 3 out of the 6 found by hidden Markov models could be detected in 
specific isolates (Figure 8). Gene 2 and 63 were found in isolate 27 (Pseudomonas Veronii). 
Gene 417 was found in isolate 212 (Sphingobacterium Multivorum). The double bands at the 
correct size for gene 417 in isolate 22 and 24 were ignored due to the ambiguous nature of 
double bands.  
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Figure 8 – Novel MBL B3 genes detected in isolates by PCR. A) Gene 2 & 63 were 
found in isolate 27 B) Gene 417 was found in isolate 212 
 
A summary of all the findings from the collected isolates is shown in Table 2. 
Table	2:	Summarized	findings	from	isolates	
 
 
ID MYLA (Seramis) Opportunistic Carba NP EDTA Positive PCR
21 Stenotropomonas maltophilia Yes
22 - (B3)
23 Sphingobacterium multivorum Yes
24 Comamonas testosteroni Yes (B3)
25 (Trichosporon asahii) (Yes)
26 Sphingobacterium multivorum Yes
27 Pseudomonas veronii No
28 Sphingobacterium multivorum Yes
29 - B1/B3
210 Stenotropomonas maltophilia Yes
211 Empedobacter brevis Yes
212 Sphingobacterium multivorum Yes B3
30 Chryseobacterium indologenes Yes
31 Stenotropomonas maltophilia Yes
32 (Trichosporon asahii) (Yes)
33 (Chryseobacterium spp.) (Yes) B1
34 Leuconostoc mesenteroides Yes B1
35 Stenotropomonas maltophilia Yes
36 Chryseobacterium indologenes Yes
37 Elizabethkingia meningoseptica Yes
51 Streptococcus pluranimalium No B1
53 -
54 -
56 Pediococcus pentosaceus No
57 -
58 Leuconostoc mesenteroides Yes B3
59 Pseudomonas veronii No B1
61 -
62 Leuconostoc mesenteroides Yes
63 - B1
64 Leuconostoc mesenteroides Yes
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6.8 11	novel	B1	and	4	novel	B3	genes	found	
DNA extracted from the initial meropenem-supplemented broths were also divided into five 
pools based on animal origin. Through PCR could the novel B1 and B3 genes be detected in 
all animal pools, 11 of the B1 and 4 of the B3 genes were detected at least once (Table 2). The 
novel genes were most common in the Amphibian pool. 
Table	3:	Distribution	of	novel	genes	in	animal	pools	
 
Animal	pool No	of	species No	of	B1	detected No	of	B3	detected Total Gene/species
A	Mammals	1 8 6 1 7 0,88
B	Mammals	2 9 5 1 6 0,67
C	Birds 7 4 2 6 0,86
D	Amphibians 8 6 3 9 1,13
E	Farm	animals 11 3 4 7 0,64
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7 Discussion	
In the fecal samples collected from zoo animals, 19 novel carbapenemase genes were 
detected, as well as 31 mostly opportunistic meropenem-resistant bacteria, 17 of them 
expressing MBLs.  7.1 Conclusions		
 Could	we	find	novel	carbapenemases	in	the	stool	of	animals	never	deliberately	exposed	to	carbapenems?		
Our study showed that novel carbapenemases are readily detectable in the gut flora of the 
sampled zoo animals. This is a result that is in line with previous studies in other regions of 
the world where carbapenemases were found in environmental and commensal bacteria.56,67 
In Walsh et al. they found plenty of the highly potent MBL NDM-1 in their Indian samples, 
but that is also in an environment where carbapenems are more liberally used.49  
 
 What	characteristics	did	they	have,	what	Ambler	class	would	it	be?	
The carbapenemase genes detected in the isolates were all Ambler class B - metallo-beta-
lactamases (MBLs), supporting the Rossolini et al. study that discovered multiple MBLs in 
predominantly environmental soil samples.68 Were they common in our sample for having a 
competitive advantage in the bacteria’s natural habitat? Or were they inadvertently selected 
for in the lab? The zinc added to the enrichment broths in this study intended to a promote 
MBLs, but it is unlikely that the concentration of 70 micromoles ZnSO4 would have an 
inhibitory effect on bacteria producing other classes of carbapenemases.  
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 What	bacteria	species	did	host	these	novel	carbapenemases	and	did	the	genes	have	the	capacity	to	transfer	to	known	human	pathogens?		
A majority of the 31 isolates were opportunistic bacteria, and when we look at the Carba NP 
positive isolates 11 of 17 were opportunistic (and 3 were not identified). 
 
The novel genes’ potential to transfer to human pathogens is of course hard to predict. 
However, the fact that they were identified in gut bacteria from animals may reduce some 
barriers for transfer to human pathogens. Forsberg et al. found identical antibiotic resistance 
genes in the environmental bacteria, pathogens and in intestinal microbiota suggestive of 
interconnectivity between the three.10 Further, whole genome sequencing of the isolates 
carrying the novel genes can provide information about the genetic context of these genes and 
thus some clues regarding their mobility potential. Some of the bacteria identified are known 
to have resident carbapenemase genes (e.g. Chryseobacter spp, Stenotrophomonas 
maltophilia). 68-71  But until the genome has been sequenced we cannot judge the mobility of 
the genes discovered in this study.  
 
A somewhat surprising find was the two isolates identified by the Seramis database as 
Trichosporon Asahii, a fungus that shouldn’t have survived the cycloheximide. One of the 
Trichosporon Asahii isolates were also positive in the Carba NP and imipenem-EDTA 
synergy tests, indicating MBL activity, a surprising finding in fungi. 
 
The type of MBL can provide some hints about its mobility. In this study 13 novel B1 genes 
and 6 novel B3 genes were detected. B1 genes are the most important class clinically with 
members like IMP, NDM and VIM, and they have predominantly been seen on plasmids.72  
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B3 (and B2), on the other hand, have most often been documented in environmental bacteria 
as resident and is not primarily associated with mobility.67  
 
 What	animal	was	colonized	with	the	bacteria?		
Time constraints reduced the ambition of pairing a specific gene to an animal pool instead of 
to an animal species. The frequency of novel carbapenemase genes were the highest in the 
amphibian pools but that is based on a very small number of hits and results should be 
interpreted carefully. The novel genes were quite evenly spread between the pools and no 
conclusion could be drawn.  
 7.2 Study	strengths	
By considering gene transmission barriers and using stool samples from zoo animals, our 
ambition was to increase the probability of finding novel carbapenemase genes that are 
compatible and able to transfer to human pathogens. of special interest would be found.  
 
The inclusion of a high number of animal species and the use of three types of inoculation 
media allowed an explorative screening of a diverse set of animal gut bacteria. Sampling zoo 
animals also gives, us a possibility to investigate the microbiota further if a carbapenemase. 
 
The hidden Markov model algorithm used to predict B1 MBLs have been validated in a 
previous study, 18 out of 21 detected novel carbapenemase genes in that study had a positive 
Carba NP test when synthesized and expressed in E. coli.56 
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The Carba NP and imipenem-EDTA synergy test are simple and robust functional tests. 
However, a potential drawback with the Carba NP test is that isolates producing OXA-48-like 
carbapenemases that are clinically relevant but often turn out false negative results due to 
their slow hydrolysis of carbapenems73. 
 7.3 Study	weaknesses	
For most animals, except the farm animals, the only contacts with humans were through food. 
Nevertheless, it cannot be excluded that detected bacterial strains and genes have been 
transmitted from humans to animals. Farm animals that had more contact with humans didn’t 
show a higher frequency of novel carbapenemases. Samples were collected from the ground 
so it is also possible that some environmental bacteria from the ground can have infiltrated the 
fecal material.  
 
A key question that remains unanswered is if horizontal gene transfer is possible between the 
commensal bacteria we collected and a pathogen. As mentioned, whole genome sequencing 
of isolates carrying the novel carbapenemases might provide some clues about their mobility 
potential. The lack of surviving colonies in the functional metagenomics test could be a result 
of incompatibility between the genes and the E.coli. However, the lack of surviving E. coli 
clones on the meropenem supplemented plates during the functional metagenoms screening 
could also be due to the fact that E. coli are often, in addition to a functional carbapenemase, 
dependent on other resistance mechanisms (such as porin loss or up-regulated efflux pumps) 
in order to survive on meropenem-supplemented plates.70  
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The initial selection of isolates was based on perceived differences among the strains that had 
grown on the plates. It is possible that some isolates are in fact identical, belonging to the 
same strain with the same animal origin but were isolated from different enrichment broths. 
Whole genome sequencing of the isolates will help in identification of any duplicate strains. 
 
The sheer number of PCR reactions required made it impossible to optimize primer design 
and annealing temperatures for each primer pair, which gave us some ambiguous and possibly 
false negative results when analyzing relevant bands on the gels. 
 7.4 Implications	
The aim with this study was to help future decision-making. If we can find novel 
carbapenemases that can migrate to pathogens, they could be screened for in the clinic with 
whole genome sequencing when it becomes more readily available.  
 
By looking at the flanking regions of the novel carbapenemase genes we might be able to 
determine the origin of the gene. If we can find the origin of resistance genes, what bacteria 
they come from, and understand the chain of events that transfer them from the environment 
to the pathogens, we might be able to break or at least slow down and intervene that process.  
 
Knowing about whatever carbapenemase genes are present in the resistome can prevent us 
from designing a next generation carbapenem drug that, before it is launched, already has an 
abundance of resistance genes luring in resistome, just waiting to break the new drug down.  
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7.5 Reflections		
All our carbapenemases were MBLs (Ambler class B) even though we didn’t intentionally 
select for them. That we didn’t find ambler class D carbapenemases (OXAs) was not as 
surprising as they are usually chromosomal. But the fact that we didn’t find any of the class A 
carbapenemases, known to be plasmid-borne was more unexpected. 
 
Our samples were from animals not exposed to carbapenems and yet their commensal bacteria 
carried an abundance of carbapenemases. In our meropenem-supplemented agar plates or 
broths we will not find any strict anaerobes and hardly any gram-positive bacteria or fungi 
(however, isolate 25 and 32 appeared to be fungi). In the Carba NP, a slow-hydrolyzing 
carbapenemase like the OXA-48s will go undetected. The applied hidden Markov models will 
only find MBL B1 and B3 genes. It is likely that we in this study heavily underestimate the 
number of carbapenemases, known and novel, in our samples. 
 
It seems likely the carbapenemases fulfill an important role for the bacteria, since we find 
them in such abundance in an environment free of selective pressure from iatrogenic 
carbapenems. The role of carbapenemases could be to modulate/inhibit carbapenem-like 
structures produced by themselves or nearby microbes, either as a signal molecule or as a way 
to control the niche. Antibiotic signal molecules can modulate immune-response (clinically 
used in rosacea and severe acne and possibly also behind the growth promotive effect of 
antibiotics in animal feeds), metabolic pathways but also CNS through the glutamate 
transporter. 9,74 Alternatively, they perform some other critical physiological function of the 
bacteria (e.g. cell wall management) or are transferred bundled with other genes that whose 
benefit outweighs the cost for the carbapenemase gene.31 The diversity could be explained by 
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carbapenemase genes being tailored over time to reduce fitness cost or to optimize the 
function in the microenvironment of the specific host bacteria.  
 7.6 Next	step	and	future	research	
The isolates identified to carry carbapenemases in this study by Carba NP and/or PCR will be 
sent for sequencing to find out if the genes are part of mobile genetic elements or not. 
Sequencing can also provide clues about the origin of the genes and identify the isolates that 
was not identified in MALDI-TOF.   
 
The chain of events needed to transfer carbapenemase genes between 
environmental/commensal bacteria and pathogens is very complex. More studies are needed 
to demonstrate the causality of the process. 
 
A specific area in need of more research would be to investigate why we see such an 
abundance of MBLs and not any of the other carbapenemases. What makes them so frequent 
in our material and what function do they perform in the bacteria out in the 
environmental/commensal community? 
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8 Sammanfattning	
Karbapenemer är en klass av antibiotika som är verksamt mot många olika typer av bakterier, 
inklusive de som många andra antibiotika inte kan ta hand om. Karbapenemer har därför en 
viktig roll vid behandlingen av allvarliga infektioner där de sjukdomsalstrande bakteriernas 
(patogenernas) känslighet för olika antibiotika är okänd. Känsligheten beror på vilka 
resistensmekanismer patogenerna har. I kliniken ser vi idag en ökad mängd infektioner där 
patogenerna inte är känsliga för karbapenemer, och den mest potenta resistensmekanismen är 
produktion av karbapenemaser, protein som kan bryta ner karbapenemer.  
 
Tidigare studier har visat att i naturen finns det resistensgener, alltså gener som kan uttrycka 
olika typer av försvar mot antibiotika och att dessa gener kan sedan vandra till våra patogener. 
Frågan vi ställde oss i denna studie var: kan vi hitta tidigare okända karbapenemaser i naturen 
som ännu inte setts i kliniken? På så sätt kan vi förstå och eventuellt påverka hur gener 
vandrar mellan miljöbakterier och patogener.  
 
För att öka sannolikheten att hitta gener som kan vandra mellan miljöbakterier och patogener 
ville vi titta på tarmfloran hos djur, en mikromiljö som i mångt och mycket är likt den som vi 
människor kan erbjuda. Ett effektivt sätt att titta på tarmfloran var att analysera spillning från 
43 djur från djurparken Nordens Ark.  
 
Proverna odlades i tre typer av buljong med olika näringsprofil samt med tre olika 
koncentrationer av meropenem (ett karbapenem) för att gynna de karbapenemasproducerande 
bakterierna. Från buljong och plattor med dessa meropenemresistenta bakterier gjordes sedan 
en rad olika analyser. Med ett Carba NP test kunde vi visa att 17 av de 31 isolerade 
bakteriestammarna på plattorna var karbapenemas-producerare och med ett annat test kunde 
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vi visa att alla dessa 17 tillhörde subgruppen metallo-β-laktamaser (MBL). 
Bakteriestammarna var opportunistiska patogener med några få undantag.  
 
Från buljongen extraherade vi DNA från samtliga prover som visade bakteriell växt, vilket 
grupperades och skickade för sekvensering. Med hjälp av en nyutvecklad bioinformatisk 
algoritm kunde 19 tidigare okända karbapenemaser (13 av B1-typ och 6 av B3-typ) hittas i 
materialet. Genom PCR kunde vi hitta 6 av B1-typerna och 3 av B3-typerna bland de 
bakteriestammar vi isolerat. Och i de 5 huvudgrupper av djur vi hade, kunde 11 B1-typer och 
4 B3-typer hittas. Mest frekvent förekom de nya generna hos groddjuren.  
 
Vi fann oväntat många okända karbapenemaser i avföringsproverna från djuren. Att alla var 
av typen MBL var också förvånande.  Det faktum att de nya karbapenemaserna kunde 
identifieras i tarmbakterier (inklusive opportunistiska patogener) från djur gör det troligare att 
utbyte kan ske med våra patogener då de kan överleva i liknande miljöer. För att verkligen 
kunna uttala oss om genernas mobilitet och ursprung kommer vi i ett senare skede sekvensera 
de insamlade isolaten separat. 
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Appendix	A:	Nordens	ark	-	Species	
Mammals 1 
1. Amur tiger (Amurtiger) 
2. Amur leopard (Amurleopard) 
3. Persian leopard (Persisk leopard) 
4. Snow leopard (Snöleopard) 
5. Pallas cat (Pallaskatt) 
6. European wildcat (Europeisk vildkatt) 
7. Przewalskis wild horse (P... vildhäst) 
8. Wolf (Varg) 
 
Mammals 2 
9. Southern Pudu (Sydlig Pudu) 
10. Reindeer (Skogsren) 
11. European ground squirrel (Sisel) 
12. Maned wolf (Manvarg) 
13. Otter (Utter) 
14. Lesser panda (Mindre panda) 
15. Tadjik markhor (Skruvhornshjort) 
16. Wolverine (Järv) 
17. Lynx (Lodjur) 
 
Birds  
18. White-naped crane (Glasögontrana) 
19. Red-crowned crane (Japansk trana) 
20. White stork (Vit stork) 
21. Northern bald ibis (Eremitibis) 
22. Ural owl (Slaguggla) 
23. Less white fronted goose (Fjällgås) 
24. Euroasian eagle owl (Bergsuv) 
 
Amphibians 
25. Mountain chicken frog (Montserrat-
groda) 
26. Green toad (Grönfläckig padda) 
27. Long nosed horned frog (Horngroda) 
28. Standings day-gecko (Standings dag-
gecko) 
29. Hermann’s tortoise (Grekisk 
landsköldpadda) 
30. Amazon milk frog (Mjölkgroda) 
31. White lipped tree frog (Asiatisk 
skumbogroda) 
32. Sand lizard (Sandödla) 
 
Farm animals 
33. The Gotland rabbit (Gotlandskanin) 
34. The Gotland sheep (Gutefår) 
35. The Blekinge duck (Blekingeanka) 
36. The Gotland pony Gotlandsruss) 
37. The Öland goose (Ölandsgås) 
38. Mountain cattle (Fjällko) 
39. Northern Swedish horse (Nordsvensk 
häst) 
40. Orust hen (Orusthöna) 
41. Old Swedish dwarf hen 
(Gammelsvensk dvärghöna) 
42. Lapp goat (Lappget) 
43. Linderöd pig (Linderödsvin)
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Appendix	B	–	Instructions	for	collection	of	stool	
samples	
Instruction for collection of animal stool samples 
There are one bucket per animal category (mammals, reptiles/amphibians, birds and farm 
animals). In each bucket you will find sampling tubes, rubber gloves, spoons, alcohol and 
tissues.  
Each tube is marked with the animal species (except for reptile and amphibians, for which 
you can take 5-6 samples of any specie of your choice and just marked the tubes accordingly). 
There are a number of spare tubes if needed. Don’t forget to mark the spare tubes with animal 
species if used.  
Keep the inside of the tubes as sterile as possible. 
Samples should be as fresh as possible.  
Samples should only be collected during Tuesday the 12th and Wednesday the 13th of August 
2014.  
Preferably mix samples from different fecal piles from the same species in the same sample 
tube in order to increase the variation. 
Samples should, if at all possible, be at least 5-10 ml for us to be able to extract DNA (tubes 
are graded).  
Use the rubber gloves. 
Samples should be collected with the included spoon that needs to be wiped thoroughly with 
alcohol between usages.  
Store the samples dark and cold (4-8 °C). To keep samples cold during sampling please use 
ice or ice packs at the bottom of the bucket. 
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